# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Dwight D. Eisenhower (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET015-SYN
- Date: 2026-01-12
- Fictional facility: St. Posthumous Health Center
- Fictional author: Russell Okonkwo, MD
- Calendar frame: modern shifted

## What we are working on

- Wants to return to a demanding full-time job and travel without bringing on another heart attack **S**
- Worries that limits on work, golf, and travel will be permanent **S**

## Your goals

- Lower LDL cholesterol below 55 mg/dL by the lipid recheck in about two months. Target: 2026-03-16. Recorded outcome: LDL cholesterol 50 mg/dL on atorvastatin and ezetimibe. **S**
- Keep blood pressure below 130/80 mmHg. Target: 2026-03-16. Recorded outcome: Blood pressure 124/76 mmHg on lisinopril 10 mg and metoprolol. **S**
- Return to full-time work and travel by the seven-month review. Target: 2026-05-11. Recorded outcome: Full-time work since late January; travelling again. **S**
- Keep at least 150 minutes a week of moderate exercise after cardiac rehabilitation. Target: 2026-05-11. Recorded outcome: Brisk walking most days and golf twice a week. **S**
- Complete twelve months of dual antiplatelet therapy without major bleeding. Target: 2026-09-28. Recorded outcome: Ticagrelor stopped at one year; one minor anterior nosebleed only. **S**

## What we agreed to do

- Dual antiplatelet therapy with aspirin 81 mg and ticagrelor 90 mg twice daily for twelve months after the infarction, then aspirin alone. Guideline: 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes (2025); CMID: Clinical Monitoring Intelligence Database, acute myocardial infarction, ischemic heart disease, hyperlipidemia, and hypertension monographs (2026) **S**
- High-intensity atorvastatin with ezetimibe added for LDL cholesterol above 55 mg/dL; recheck lipids 4 to 12 weeks after the change, then every 3 to 12 months. Guideline: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); CMID: Clinical Monitoring Intelligence Database, acute myocardial infarction, ischemic heart disease, hyperlipidemia, and hypertension monographs (2026) **S**
- Metoprolol succinate and lisinopril for blood pressure below 130/80; basic metabolic panel 1 to 2 weeks after an ACE inhibitor change, then every 6 months; reassess the beta-blocker at one year. Guideline: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); CMID: Clinical Monitoring Intelligence Database, acute myocardial infarction, ischemic heart disease, hyperlipidemia, and hypertension monographs (2026) **S**
- Cardiology consultation to establish local cardiology care, reassess left ventricular function, and advise on return to full-time work and on the duration of antiplatelet and beta-blocker therapy. Guideline: 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes (2025); 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023) **S**
- After cardiac rehabilitation, a home maintenance program of brisk walking and golf, a Mediterranean-style diet, staying tobacco free, PHQ-2 depression screening at visits, and a written chest-pain plan with sublingual nitroglycerin. Guideline: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); CMID: Clinical Monitoring Intelligence Database, acute myocardial infarction, ischemic heart disease, hyperlipidemia, and hypertension monographs (2026) **S**
- Yearly influenza vaccine, pneumococcal vaccine, RSV vaccine, and current COVID-19 vaccine. Guideline: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); CMID: Clinical Monitoring Intelligence Database, acute myocardial infarction, ischemic heart disease, hyperlipidemia, and hypertension monographs (2026) **S**

## Follow-up

- 2026-01-12: Primary care visit to establish care after myocardial infarction and plan a return to full-time work **S**
- 2026-01-26: Two-week blood pressure and kidney check, echocardiogram, and cardiology consultation **S**
- 2026-03-16: Lipid review nine weeks after adding ezetimibe **S**
- 2026-05-11: Seven-month coronary disease review after return to full-time work **S**
- 2026-09-28: One-year review after myocardial infarction: end of dual antiplatelet therapy **S**
- 2026-10-19: Initial annual wellness visit **S**

This teaching document does not replace care from a qualified clinician.
